These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19166695)

  • 1. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance.
    Ruisinger JF; Backes JM; Gibson CA; Moriarty PM
    Am J Cardiol; 2009 Feb; 103(3):393-4. PubMed ID: 19166695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.
    Backes JM; Venero CV; Gibson CA; Ruisinger JF; Howard PA; Thompson PD; Moriarty PM
    Ann Pharmacother; 2008 Mar; 42(3):341-6. PubMed ID: 18285559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of once weekly rosuvastatin among patients with a prior statin intolerance.
    Backes JM; Moriarty PM; Ruisinger JF; Gibson CA
    Am J Cardiol; 2007 Aug; 100(3):554-5. PubMed ID: 17659946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.
    Kennedy SP; Barnas GP; Schmidt MJ; Glisczinski MS; Paniagua AC
    J Clin Lipidol; 2011; 5(4):308-15. PubMed ID: 21784377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
    Asztalos BF; Le Maulf F; Dallal GE; Stein E; Jones PH; Horvath KV; McTaggart F; Schaefer EJ
    Am J Cardiol; 2007 Mar; 99(5):681-5. PubMed ID: 17317371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.
    Gadarla M; Kearns AK; Thompson PD
    Am J Cardiol; 2008 Jun; 101(12):1747-8. PubMed ID: 18549851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study).
    Milionis HJ; Rizos E; Kostapanos M; Filippatos TD; Gazi IF; Ganotakis ES; Goudevenos J; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2006 Jun; 22(6):1123-31. PubMed ID: 16846545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.
    Mackie BD; Satija S; Nell C; Miller J; Sperling LS
    Am J Cardiol; 2007 Jan; 99(2):291. PubMed ID: 17223437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approximate equivalent rosuvastatin doses for temporary statin interchange programs.
    Kendrach MG; Kelly-Freeman M
    Ann Pharmacother; 2004; 38(7-8):1286-92. PubMed ID: 15187217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Christogiannis LG; Bairaktari ET; Tselepis AD; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):5-13. PubMed ID: 19246334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding options with a wider range of rosuvastatin doses.
    Olsson AG
    Clin Ther; 2006 Nov; 28(11):1747-63. PubMed ID: 17212997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
    Ballantyne CM; Weiss R; Moccetti T; Vogt A; Eber B; Sosef F; Duffield E;
    Am J Cardiol; 2007 Mar; 99(5):673-80. PubMed ID: 17317370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternate day rosuvastatin, an underutilized option in statin intolerant hyperlipidemic patients: a case report and literature review.
    Gopalagowda BH; Cutchins C; Cutchins DC; Peiris AN
    Tenn Med; 2011 Feb; 104(2):49-51. PubMed ID: 21387899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels.
    Ai M; Otokozawa S; Asztalos BF; Nakajima K; Stein E; Jones PH; Schaefer EJ
    Am J Cardiol; 2008 Feb; 101(3):315-8. PubMed ID: 18237592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia.
    Wongwiwatthananukit S; Sansanayudh N; Dhummauppakorn R; Kitiyadisai C
    Ann Pharmacother; 2006 Nov; 40(11):1917-23. PubMed ID: 17003082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
    Stein EA; Amerena J; Ballantyne CM; Brice E; Farnier M; Guthrie RM; Harats D; Ma PT; Le Maulf F; Melezínková H; Gold A; Sager P
    Am J Cardiol; 2007 Nov; 100(9):1387-96. PubMed ID: 17950795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of rosuvastatin.
    Shepherd J; Hunninghake DB; Stein EA; Kastelein JJ; Harris S; Pears J; Hutchinson HG
    Am J Cardiol; 2004 Oct; 94(7):882-8. PubMed ID: 15464670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function.
    Pirro M; Schillaci G; Romagno PF; Mannarino MR; Bagaglia F; Razzi R; Pasqualini L; Vaudo G; Mannarino E
    J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):14-21. PubMed ID: 19158317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers.
    Li JJ; Yang P; Liu J; Jia YJ; Li ZC; Guo YL; Wu NQ; Tang YD; Jiang LX
    Clin Chim Acta; 2012 Jan; 413(1-2):139-42. PubMed ID: 21983163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.